Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Dickson

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 18, 2023
Operationalizing the centiloid scale for [<sup>18</sup>F]florbetapir PET studies on PET/MRIWilliam Coath, Marc Modat, M Jorge Cardoso, et al.
The Lancet. Neurology|August 25, 2019
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological studyChristopher A Lane, Josephine Barnes, Jennifer M Nicholas, et al.
JACC. Cardiovascular Imaging|October 13, 2014
Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 StudySergey V Nesterov, Emmanuel Deshayes, Roberto Sciagrà, et al.
Brain Communications|September 8, 2023
Neuroimaging, clinical and life course correlates of normal-appearing white matter integrity in 70-year-oldsSarah-Naomi James, Emily N Manning, Mathew Storey, et al.
Lancet (London, England)|February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|May 18, 2023
Operationalizing the centiloid scale for [<sup>18</sup>F]florbetapir PET studies on PET/MRIWilliam Coath, Marc Modat, M Jorge Cardoso, et al.
The Lancet. Neurology|August 25, 2019
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological studyChristopher A Lane, Josephine Barnes, Jennifer M Nicholas, et al.
JACC. Cardiovascular Imaging|October 13, 2014
Quantification of myocardial blood flow in absolute terms using (82)Rb PET imaging: the RUBY-10 StudySergey V Nesterov, Emmanuel Deshayes, Roberto Sciagrà, et al.
Brain Communications|September 8, 2023
Neuroimaging, clinical and life course correlates of normal-appearing white matter integrity in 70-year-oldsSarah-Naomi James, Emily N Manning, Mathew Storey, et al.
Lancet (London, England)|February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Pageof 10